Group sales at Roche were flat in 2010 reflecting a decline in influenza product sales and the impact of lower US and European healthcare spending. Restructuring measures cost the company CHF 1.3 billion (€1 billion) last year. ---Subscribe to MedNous to access this article--- Company News
